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The adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a key sensor of cellular energy.
Once activated, it switches on catabolic pathways generating adenosine triphosphate (ATP), while
switching off biosynthetic pathways consuming ATP. Pharmacological activation of AMPK by metformin
holds a therapeutic potential to reverse metabolic abnormalities such as type 2 diabetes and nonalco-
holic fatty liver disease. In addition, altered metabolism of tumor cells is widely recognized and AMPK is
a potential target for cancer prevention and/or treatment. Panax ginseng is known to be useful for
treatment and/or prevention of cancer and metabolic diseases including diabetes, hyperlipidemia, and
obesity. In this review, we discuss the ginseng extracts and ginsenosides that activate AMPK, we clarify
the various mechanisms by which they achieve this, and we discuss the evidence that shows that ginseng
or ginsenosides might be useful in the treatment and/or prevention of metabolic diseases and cancer.
opyright  2013, The Korean Society of Ginseng, Published by Elsevier. Open access under CC BY-NC-ND license. 1. Introduction
Adenosine monophosphate (AMP)-activated protein kinase
(AMPK) is a somewhat old kinase because its activity was ﬁrst
documented in 1973 as a negative regulator of acetyl-coenzyme A
(CoA) carboxylase (ACC) and 3-hydroxy-3-methyl-glutaryl-CoA
reductase (HMGR) in the biosynthesis of fatty acids and cholesterol,
respectively [1,2]. AMPK is a highly preserved sensor of cellular
energy status, and appears to exist in essentially all eukaryotes as
heterotrimeric complexes composed of a catalytic a subunit and
regulatory b and g subunits. The a subunit contains the kinase
domain, with the conserved threonine residue that is the target for
upstream kinases [liver kinase B1 (LKB1) and Ca2þ-activated
calmodulin-dependent kinase kinases (CaMKKs)] located within
the activation loop. Phosphorylation at Thr172 is required for ki-
nase activity and function in all species fromyeast to man, and with
the human kinase, causes >100-fold activation [3]. In mammals, all
three subunits have multiple isoforms encoded by distinct genes
(a1, a2; b1, b2; g1, g2, g3), which assemble to form up to 12 het-
erotrimeric combinations [4]. The functions of the different subunit
isoforms remain unclear, although there is tissue-speciﬁcgy and Clinical Pharmacy, College
inseng, Published by Elsevier. Opeexpression of some isoforms, and there is evidence that different
isoforms may target complexes to speciﬁc subcellular locations.
Because the energy status of the cell is a crucial factor in all aspects
of cell function, it is not surprising that AMPK has umpteen
downstream targets whose phosphorylation mediates dramatic
changes in cell metabolism, cell growth, and other functions.
Obesity and the metabolic syndrome represent a major health
problem in both Western and developing countries. Considering
the role of AMPK in regulating energy balance at both the cellular
and whole-body levels, this kinase occupies a pivotal position in
studies regarding obesity, diabetes, and the metabolic syndrome
[5]. By direct phosphorylation of metabolic enzymes and tran-
scription factors, AMPK switches on catabolic pathways, such as the
uptake of glucose and fatty acids, and their metabolism by mito-
chondrial oxidation and glycolysis. In addition, AMPK switches off
anabolic pathways, such as the synthesis of glucose, glycogen, and
lipids in the liver. By promoting muscle glucose uptake and meta-
bolism and by inhibiting hepatic gluconeogenesis, AMPK activation
can explain the antidiabetic action of metformin. Type 2 diabetes is
primarily caused by insulin resistance, which is strongly associated
with excess triglyceride storage in liver and muscle. By switchingof Pharmacy, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701,
n access under CC BY-NC-ND license. 
J Ginseng Res 2014;38:83e8884off the synthesis of fatty acids and triglycerides and enhancing fat
oxidation, AMPK activation might also explain the insulin-sensi-
tizing action of metformin.
The uncontrolled proliferation of cancer cells is supported by a
corresponding adjustment of energy metabolism. Nowadays,
altered metabolism of tumor cells is widely recognized as an
emerging hallmark and a potential drug target in cancer cells.
Protein synthesis is the best-characterized process regulated by the
mammalian target of rapamycin complex 1 (mTORC1). mTORC1
plays a key role in translational control by phosphorylating lots of
translation regulators, including S6 kinase 1 (S6K1) [6]. The syn-
thesis of fatty acids, triglycerides, cholesterol, RNA, and proteins are
all upregulated in tumor cells. Notably, because protein synthesis
requires a myriad of cellular energy, AMPK activation induced by
metabolic stress signiﬁcantly inhibits protein synthesis, resulting in
AMPKemTORC1 crosstalk: AMPK attenuates mTORC1 signaling
through phosphorylation and activation of tuberous sclerosis 2 [7],
a negative regulator of mTORC1. AMPK also directly phosphorylates
Raptor, which induces 14-3-3 binding to raptor and repression of
mTORC1 activity [8]. Other ﬁndings that AMPK caused the inhibi-
tion of progress through the cell cycle [9], and that the mechanism
of AMPK activation required the presence of the tumor suppressor
LKB1 [10e12] also gave us the idea that AMPK activators might be
beneﬁcial in the prevention and/or treatment of cancer. AMPK
activation switches off all of these pathways and would therefore
be expected to exert an antitumor effect, reinforced by its ability to
cause cell-cycle arrest. These effects of AMPK might explain the
tumor suppressor effects of the upstream kinase LKB1 [13], as well
as ﬁndings that metformin usage reduces the risk of cancer in di-
abetics [14] and that metformin and other AMPK activators
(phenformin, A-769662) delay the onset of tumorigenesis in a
mouse model [15].
Over recent years, a plethora of naturally occurring compounds
including ginseng and ginsenosides have been reported to activate
AMPK in intact cells. These natural products include resveratrol
from grapes [16], epigallocatechin-3-gallate (EGCG) from green tea
and capsaicin from chili peppers [17], curcumin from turmeric [18],
as well as four compounds derived from traditional Chinese med-
icine, berberine from Chinese Goldthread [19], hispidulin from
Snow Lotus [20], licochalcone A from Glycyrrhiza and Brassica rapa
[21], and betulinic acid from Betula [22]. Ginseng is one of the most
popular and bestselling herbal medicines worldwide. Ginseng has
been used as a medicine and/or as a neutraceutical by healthy and
ill individuals all around the world. Many clinical and animal
studies on ginseng have been performed to characterize its thera-
peutic properties, which include improving physical performance
[23,24] and sexual function [25,26], treating cancer [27,28], dia-
betes [29e31], and hypertension [32,33]. In this article, we review
the mechanisms by which AMPK is activated by ginseng extracts or
ginsenosides, well-known active components found in ginseng.
Ginseng was used for preventing and/or treating metabolic disor-
ders and cancer prior to when it was realized that ginseng and
ginsenosides seem to be AMPK activators.
2. Pharmacological activities of ginseng as an AMPK activator
AMPK activators derived from medicinal plants have disparate
chemical structures and it was difﬁcult to see how they activate
AMPK. However, it has now been shown that some inhibit mito-
chondrial function, either inhibiting the respiratory chain
(berberine and licochalcone A) or the adenosine triphosphate (ATP)
synthase (EGCG and resveratrol), or acting as an uncoupler (cur-
cumin). Consistent with the idea that this is how they activate
AMPK, berberine and resveratrol increased the AMP:ATP ratio in
cultured cells and failed to activate AMPK in cells expressing theAMP/ADP-insensitive R531G [34]. Why do so many plants produce
compounds that are mitochondrial inhibitors and hence AMPK
activators? Respiratory chain and ATP synthase might have po-
tential binding sites for xenobiotic compounds, and the production
of mitochondrial poisons might be a suitable mechanism for plants
to deter infection by pathogens. To date, 31 English language arti-
cles were published according to a search of the PubMed database
using keywords “ginseng”, “ginsenoside”, and “AMPK”. Among
them, 19 articles are related to metabolic diseases, six articles are
related to cancer, and six articles are related to other pharmaco-
logical activities, including two review articles.
2.1. Effects on metabolic diseases
Beneﬁcial effects of ginseng and its active ingredients on meta-
bolic disorders have been known from many clinical and animal
studies. Table 1 summarizes the effects of ginseng associated with
AMPK activation in animal and cell studies. AMPK phosphorylates
serine residues surrounded by a well-deﬁned recognition motif
[8,35]. Fig. 1 shows targets involved in the acute and chronic regu-
lation of metabolism. Ginseng or ginsenosides can work on one
speciﬁc target and pathway or more than one target, or even other
targets not shown in Fig. 1, including glycolysis, lipolysis, glycogen
synthesis, protein synthesis, forkhead box transcription factor class
O1/3a (FOXO1/3a) target genes, genes involved in oxidative stress
resistance, cytochromeP450drugmetabolismgenes, and amplitude
and period of expression of circadian genes.
(1) AMPKactivates glucose transporter4 (GLUT4)-mediatedglucose
uptake in muscle via phosphorylation of TBC1 domain family
member 1 (TBC1D1) [36]. Lee et al [37] demonstrated that higher
expression levels of GLUT4 and its transcription factor (myocyte
enhancer factor 2, MEF-2) were observed in the gastrocnemius
muscle of Korean red ginseng (KRG)-treated Otsuka Long-Evans
Tokushima Fatty (OLETF) rats compared with untreated rats.
(2) AMPK activates fatty acid uptake via translocation of the
transporter CD36 to the plasma membrane [38]. Kim et al [39]
showed that compound K (CK) increased gene expressions of
peroxisome proliferator activated receptor a (PPARa) and
CD36, a transcriptional regulator for lipid catabolism and up-
take in human hepatoma cells.
(3) AMPK activates fatty acid oxidation by phosphorylating and
inactivating the mitochondria-associated isoform of ACC2, thus
lowering malonyl-CoA, an inhibitor of fatty acid uptake into
mitochondria via the carnitine palmitoyltransferase system
[40]. Shen et al [41] demonstrated that Rb1 reduced fatty liver in
obese rats, and this effect was primarily due to increased fatty
acid oxidation via activation of the AMPK signaling pathway.
(4) AMPK inhibits fatty acid synthesis by directly phosphorylating
and inactivating the cytosolic isoform of ACC1 [42].
(5) AMPK inhibits triglyceride and phospholipid synthesis by
causing inactivation of the ﬁrst enzyme involved in their syn-
thesis, glycerol-3-phosphate acyl transferase (GPAT) [43]. Yuan
et al [44] demonstrated that CK has a beneﬁcial effect on lipid
metabolism via activation of AMPK in the liver of C57BL/ksJ db/
db mice. CK (also known as IH-901) signiﬁcantly reduced the
expressions of sterol response element binding protein 1
(SREBP1) and its target genes such as fatty acid synthase (FAS),
stearoyl-CoA desaturase 1 (SCD1), and GPAT in the liver of mice.
(6) AMPK inhibits cholesterol synthesis by direct phosphorylation
and inactivation of HMGR [45]. Lee et al [46] showed that
ginsenoside Rg3 reduces lipid accumulation in HepG2 cells.
Rg3 decreased mRNA expression of SREBP2, a transcriptional
regulator of genes involved in cholesterol metabolism, and
expression of HMGR, which catalyzes a rate-limiting step in
Table 1
Effects of Ginseng on Metabolic Diseases in Relation to AMPK Activation
Material Cell line/animal Dose/duration Effects and molecular mechanism Refs
Rb1 HFD-fed Long-Evans rats 10 mg/kg, i.p. for 4 weeks Decreased hepatic fat accumulation [41]
Rat primary hepatocytes Enhanced fatty acid oxidation via increase in CPT1 activity
Increased AMP/ATP ratio
Rb2 H4IIE cells 0.01e1 mM Inhibited gluconeogenesis via induction of SHP gene
expression and suppression of ROSeJNK pathway in
palmitate-induced insulin resistance
[56]
Rc C2C12 myotubes 50e200 mM Induced glucose uptake and p38 MAPK phosphorylation [57]
AMPK and p38 activation was mediated by ROS production
HepG2 cells 0.1e10 mM Decreased hepatic triglyceride and cholesterol levels [46]
Inhibited expression of SREBP-2 and HMGR
Rg3 3T3-L1 adipocytes 20e80 mM Inhibited adipocyte differentiation by activation of AMPK
and inhibition of PPAR-g
[58]
C2C12 myotubes 10e100 mM 20(S)-Rg3 showed higher pharmacological effects in
insulin secretion and AMPK activation than 20(R)-Rg3
[59]
3T3-L1 adipocytes 0.001e0.1 mM Enhanced glucose uptake and stimulated GLUT4
translocation by activation of AMPK and PI3K pathway
[60]
Inhibited TG accumulation
CK (IH-901) C57BL/KsJ db mice 10e25 mg/kg, p.o. for 6 weeks Plasma glucose decreased by 20.7% at 25 mg/kg [44]
Plasma insulin increased by 3.4 times in 25 mg/kg-treated mice
C2C12 myotubes 5e20 mM Stimulated glucose uptake and overexpression of GLUT4
via activation of AMPK and PI3KeAkt pathway
[39]
Inhibited TG accumulation
HepG2 cells 5e20 mM Inhibited lipogenesis by modulating LKB1eAMPKeSREBP1
signaling pathway, and stimulated lipolysis via
upregulations of PPAR-a and CD36
Re HepG2 cells 5e20 mM Inhibited hepatic glucose production and lipogenesis via
activation of AMPK signaling pathway
[50]
HFD-fed C57BL/6J mice 5e20 mg/kg, p.o. for 3 weeks Lowered blood glucose and TG levels by 18.9% and 29.5%
in 20 mg/kg of Re-treated mice




Rg1 C2C12 myotubes 10e40 mM Improved insulin resistance [61]
Enhanced glucose uptake by overexpression of GLUT4 via
activation of AMPK
HepG2 cells 10e40 mM Inhibited hepatic glucose production by phosphorylation
of LKB1, AMPK, and FoxO1
[55]
PEPCK and G6Pase activities were decreased
Rg2 HepG2 cells 5e20 mM Inhibited hepatic glucose production by phosphorylation




KRG Otsuka Long-Evans 200 mg/kg, p.o. for 40 weeks Improved insulin sensitivity [37]
Tokushima Fatty rats Promoted fatty acid oxidation and enhanced mitochondrial
biogenesis and glucose utilization by activation of AMPK
Ginsam Otsuka Long-Evans 300e500 mg/kg, p.o. for 8 weeks Plasma insulin levels were lowered, and this effect was




CK, compound K; CPT1, carnitine palmitoyltransferase-1; FoxO1, forkhead box class O1; G6Pase; glucose-6-phosphatase; GLUT4, glucose transporter 4; GSK3b, glycogen
synthase kinase 3b; HFD, high fat diet; HMGR, 3-hydroxy-3-methyl glutaryl coenzyme A reductase; i.p., intraperitoneal administration; JNK, c-Jun NH2-terminal kinase; KRG,
Korean red ginseng; LKB1, liver kinase B1; MAPK, mitogen-activated protein kinase; PEPCK, phosphoenolpyruvate carboxykinase; PI3K, phosphatidylinositol 3-kinase; p.o.,
oral administration; PPAR, peroxisome proliferator-activated receptor; ROS, reactive oxygen species; SHP, orphan nuclear receptor small heterodimer partner; SREBP, sterol
regulatory element binding protein; TG, triglyceride.
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manner.
(7) AMPK phosphorylates cyclic AMP response element binding
protein (CREB)-regulated transcription coactivator- 2 (CRTC2),
causing it to bind 14-3-3 proteins, thus retaining it in the
cytoplasm and inhibiting activation of genes encoding gluco-
neogenic enzymes such as phosphoenolpyruvate carbox-
ykinase (PEPCK) and glucose-6-phosphatase (G6Pase) in the
liver [47]. Yuan et al [48] revealed that ginsenoside Rg2 inhibits
hepatic glucose production through activation of the AMPK
signaling pathway. Although phosphorylation of CRTC2 by Rg2
was not shown in this article, Rg2 reduced phosphorylation of
CREB causing interruption of the formation of the CREBeCRTC2
complex, which resulted in suppression of gene expression of
gluconeogenic enzymes such as PEPCK and G6Pase.(8) AMPK phosphorylates SREBP1, preventing its proteolytic pro-
cessing and translocation into the nucleus and thus inhibiting
transcription of lipogenic genes, including those encoding ACC1
and FAS [49]. Our group reported that CK and Re attenuate he-
patic lipid accumulation in HepG2 cells [39,50]. CK and Re
attenuated the expression of SREBP1, central to the intracellular
surveillance of lipid catabolism and de novo biogenesis, in time-
and dose-dependent manners. Genes for SCD1 and FAS, well-
known target molecules of SREBP1, were also suppressed.2.2. Effects on cancer
Beneﬁcial effects of ginseng or ginsenosides on cancer associ-
ated with the AMPK signaling pathway were reported since 2009,
Fig. 1. Acute and chronic metabolic effects of adenosine monophosphate (AMP)-activated protein kinase (AMPK) activation. See text for numbering and key to acronyms. Blue
arrows indicate activation, red lines with a bar at the end indicate inhibition. Suppression of hepatic glucose production and lipid accumulation by ginsenosides were mainly
mediated by liver kinase B1 (LKB1)eAMPK signaling pathways. ACC, Acetyl coenzyme A carboxylase; ATP, adenosine triphosphate; CaMKK, calmodulin-dependent kinase kinase;
CRTC, regulated transcription coactivator; GLUT4, glucose transporter 4; G6Pase, glucose-6-phosphatase; GPAT, glutamine phosphoribosylpyrophosphate amidotransferase; HMGR,
3-hydroxy-3-methylglutaryl-coenzyme A reductase; PEPCK, phosphoenolpyruvate carboxykinase; SREBP, sterol response element binding protein; TG, triglyceride.
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our group reported that CK and Rg3 induce apoptosis via the
CaMKKeAMPK signaling pathway in HT-29 colon cancer cells, and
these activities were conﬁrmed using either compound C (a
chemical inhibitor of AMPK) or small interfering RNA (siRNA) for
AMPK or STO-609 (a chemical inhibitor of CaMKK) [51,52]. Kim et al
[53] also reported that CK inhibits cell growth, induces apoptosis
via generation of reactive oxygen species, as well as decreasing
cyclooxygenase-2 expression and prostaglandin E2 levels. These
effects were induced via an AMPK-dependent pathway and were
abrogated by a speciﬁc AMPK inhibitor, compound C [53]. More
recently, Hwang et al [54] reported that 20-O-b-D-glucopyranosyl-
20(S)-protopanaxadiol (20-GPPD), a metabolite of ginseng saponin,
causes apoptosis of colon cancer cells through the induction of
cytoplasmic Ca2þ. 20-GPPD decreased cell viability, increased
annexin V-positive early apoptosis, and induced sub-G1 accumu-
lation and nuclear condensation of CT-26murine colon cancer cells.
Although 20-GPPD-induced activation of AMPK played a key role in
the apoptotic death of CT-26 cells, LKB1, a well-known upstream
kinase of AMPK, was not involved in this activation [54].
Although many studies support the tumor-suppressive role of
AMPK, some evidence suggests that the metabolic function of
AMPKmight be overridden by oncogenic signals so that tumor cells
use AMPK activation as a survival strategy to gain growth. During
certain stages of tumor development, AMPKmight act as protectivemachinery against metabolic stress such as nutrient deprivation
and hypoxia. Thus, investigation to deﬁne at which stage of cancer
progression might represent a more relevant strategy to employ
AMPK activation for cancer treatment is clearly warranted.
3. Perspectives
AMPK is a critical metabolic sensor that ﬁnely regulates the en-
ergy homeostasis of cells. Therefore, it has been suggested as a po-
tential target for metabolic disorders and cancer. A plethora of
chemical agents reported to activate AMPK exist, most notably
metformin and 5-aminoimidazole-4-carboxamide ribonucleoside
(AICAR). Most of these chemicals, except A-769662, known to be a
direct AMPK activator developed in 2005 by Abbott Laboratories,
Abbott Park, Illinois, USA, activate AMPK indirectly with some other
effects. At this time, we do not know exactly how ginseng or ginse-
nosides activate AMPK although LKB1 [39,48,50,55] or the calcium-
dependent pathway involving phosphorylation of AMPK by CAMKK
would be suggested. As alternative or additional explanations,
mechanisms involving either an increase in the AMP:ATP ratio [41],
inhibition of mitochondrial ATP synthesis, or the SIRT1-dependent
pathway via increase in nicotinamide adenine dinucleotide (NADþ)
levels should be tested to elucidate further how ginseng or ginse-
nosides activate AMPK. Despite recent advances in the mechanistic
understanding of AMPK activation by ginseng or ginsenosides,
K.J. Jeong et al / AMPK: a target for ginseng 87several key questions still remain. Is there a positive correlation be-
tween antimetabolic or anticancer activities of ginseng (and ginse-
nosides) and theAMPK signaling pathway as a primary target? If yes,
how do ginseng or ginsenosides activate AMPK? Do they activate
AMPK directly or indirectly? What are the therapeutic and toxico-
logical consequences ofAMPKactivation?TheAMPKﬁeldof research
isnowwell developedandshouldprovidenewandexcitingnovelties
regarding the application of AMPK in preventive and clinical medi-
cine.With the concerted research efforts of many laboratories, these
challenges may be addressed soon.Conﬂicts of interest
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